Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-863 in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
jRCT2031260223Phase 2Not yet recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of NS-863 in pulmonary hypertension associated with interstitial lung disease (PH-ILD) (3 arms), sponsored by NS Pharma, Inc. Primary endpoints: Change in pulmonary vascular resistance at Week 24 and Adverse events up to approximately 24 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
NS-863
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on jRCT2031260223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260223.